In the liver, EPO inhibited gluconeogenesis, attenuated obesity-related inflammatory cytokine expression and production of TNF-α and IL-6, reduced the activation of NFκB and inflammatory signaling, and enhanced insulin-related PI3K signaling (Meng et al., 2013). Here, EPO is linked to obesity due to melanocortin 4 receptor deficiency.